Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers

Ranked by citations 18 months after publication

Class of 2026 (Papers Published in 2024)

What topics and trends defined most-cited Acute Myeloid Leukemia Research research in the Class of 2026?

AML research in the Class of 2026 is driven by measurable residual disease (MRD) surveillance and venetoclax-azacitidine combination therapies. Topic evolution shows a dramatic 5-fold surge in KMT2A rearrangement and Menin inhibitor studies, while general single-cell transcriptomics and isolated baseline gene mutation analyses showed relative declines.

See details ↓

Updated July 31, 2026

At a glance

Field
Acute Myeloid Leukemia Research
Cohort label
Class of 2026 (2024 publications)
Papers analyzed
6,270
Papers ranked
20
Top topics in ranked papers
Measurable residual disease (MRD), Venetoclax, KMT2A rearrangement, Azacitidine, Menin inhibitor
Publication window
Jan 1, 2024 – Dec 31, 2024
Eligibility
Research articles; reviews excluded
Citation window
18 months post-publication
18m citation range
36–147
Data source
OpenAlex · Retrieved Jul 2026
License
CC BY 4.0

Rankings

20 papers ranked by 18-month citation count

#1 of 6,270
14718m citations

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner et al.Blood202410.1182/blood.2024025409

Hartmut DöhnerUlm University Hospital, Germany

European LeukemiaNet (ELN)European LeukemiaNet (ELN) risk classificationAcute myeloid leukemia (AML)Low-intensity therapyIntensive chemotherapyyounger adults with AML2024 ELN recommendationsRisk stratificationtreatment-specific risk assessment
Badge
#2 of 6,270
13618m citations

Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Ghayas C Issa et al.Journal of Clinical Oncology202410.1200/jco.24.00826

Ghayas C IssaThe University of Texas MD Anderson Cancer Center, United States

RevumenibMenin inhibitorKMT2A rearrangementRelapsed/refractory acute leukemiaMenin-KMT2A interactionAUGMENT-101Complete remission (CR)CR with partial hematologic recoveryNPM1 mutationdifferentiation syndromeQT interval prolongationMeasurable residual disease (MRD)cytochrome P450 inhibitortargeted therapyphase II trial
Badge
#3 of 6,270
12018m citations

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>

Mark J Levis et al.Journal of Clinical Oncology202410.1200/jco.23.02474

Mark J LevisJohns Hopkins University, United States

gilteritinibFLT3 internal tandem duplication (FLT3-ITD)Allogeneic hematopoietic stem cell transplantation (allo-HSCT)post-transplant maintenanceFLT3 inhibitorMeasurable residual disease (MRD)relapse-free survivalOverall survivalMRD-based therapyFirst complete remissionAML
Badge
#4 of 6,270
11418m citations

Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

Keith W Pratz et al.American Journal of Hematology202410.1002/ajh.27246

Keith W. PratzUniversity of Pennsylvania, United States

VenetoclaxAzacitidineAcute myeloid leukemia (AML)chemotherapy-ineligible patientsVIALE-A trialOverall survivalcomplete remission with/without blood count recoveryCR/CRiIDH1/2 mutationsMeasurable residual disease (MRD)thrombocytopenianeutropeniaNewly diagnosed acute myeloid leukemiaIntensive chemotherapylong-term follow-uphazard ratio
Badge
#5 of 6,270
10418m citations

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner et al.Blood202410.1182/blood.2024024944

Hartmut DöhnerUlm University Hospital, Germany

Venetoclax plus hypomethylating agent therapyEuropean LeukemiaNet (ELN) risk classificationVIALE-A trialTP53 mutationFLT3 internal tandem duplication (FLT3-ITD)NRAS mutationKRAS mutationadverse-risk AMLtreatment-naive patientsOverall survivalMolecular signaturesbioinformatic algorithmRisk stratificationELN 2017 risk classificationELN-2022 risk classificationplacebo-azacitidinehigher-benefit groupintermediate-benefit grouplower-benefit group
Badge
#6 of 6,270
8018m citations

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Eunice S Wang et al.The Lancet Oncology202410.1016/s1470-2045(24)00386-3

Eunice S. WangRoswell Park Comprehensive Cancer Center, United States

ZiftomenibRelapsed/refractory acute myeloid leukemiaKOMET-001Phase 1 clinical trialmulti-cohort studyMenin inhibitorKMT2A rearrangementNPM1 mutationdose escalationmaximum tolerated dosedifferentiation syndromeComplete remission (CR)Measurable residual disease (MRD)pharmacokineticstarget engagementMEIS1 suppressionsafety profileadverse events
Badge
#7 of 6,270
7618m citations

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

Junya Sango, Saul Carcamo, Maria Sirenko, Abhishek Maiti et al.Nature202410.1038/s41586-024-08137-x

Eirini P. PapapetrouIcahn School of Medicine at Mount Sinai, United States

RAS mutationsAcute myeloid leukemia (AML)leukaemia stem cellsVenetoclaxgranulocyte–monocyte progenitorsmonocytic diseaseClonal evolutionBCL2 family gene expressionrelapsed/refractory diseaseDriver mutationstemporal acquisition patternscommitted progenitorshaematopoietic hierarchyTherapy resistancemyelomonocytic lineageLSC target cell restriction
Badge
#8 of 6,270
7518m citations

Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021

Yeming Zhou, Guiqin Huang et al.Biomarker Research202410.1186/s40364-024-00649-y

Dengju LiHuazhong University of Science and Technology, China

Acute myeloid leukemia (AML)Global Burden of Disease studyage-standardized ratesdisability-adjusted life yearsSocio-demographic indexsmokinghigh body mass indexoccupational benzene exposureoccupational formaldehyde exposureepidemiological patternsage-specific burdensex-specific burdenSDI-stratified analysisdeveloped versus developing nationsrisk factor attribution
Badge
#9 of 6,270
7418m citations

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML

Nicholas J Short et al.Journal of Clinical Oncology202410.1200/jco.23.01911

Nicholas J ShortThe University of Texas MD Anderson Cancer Center, United States

AzacitidineVenetoclaxgilteritinibFLT3-mutated AMLFLT3-internal tandem duplicationFLT3 internal tandem duplication (FLT3-ITD)oral FLT3 inhibitorNewly diagnosed acute myeloid leukemiaRelapsed/refractory acute myeloid leukemiaComplete remission (CR)Complete remission with incomplete hematologic recovery (CRi)CRiMeasurable residual disease (MRD)MRD negativityrelapse-free survivalOverall survivalmorphologic leukemia-free statemyelosuppressionmaximum tolerated dosephase I/II trial
Badge
#10 of 6,270
5918m citations

Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis

Nicholas Bernstein, Michael Spencer Chapman et al.Nature Genetics202410.1038/s41588-024-01755-1

Robert L. Cohen, Jyoti NangaliaCalico Life Sciences LLC, United States

Clonal hematopoiesissomatic mutationspositive selectionUK BiobankWhole exome sequencingZBTB33ZNF318ZNF234SPRED2SH2B3SRCAPSIK3SRSF1CHEK2CCDC115CCL22BAXYLPM1MYD88MTA2
Badge
#11 of 6,270
5818m citations

Adult skull bone marrow is an expanding and resilient haematopoietic reservoir

Bong Ihn Koh et al.Nature202410.1038/s41586-024-08163-9

Bong Ihn Koh, Ralf H. AdamsMax Planck Institute for Molecular Biomedicine, Germany

skull bone marrowhaematopoietic stem cell self-renewalbone marrow microenvironmentvascular growthhaematopoietic outputpro-inflammatory cytokinesadipogenesisvascular integrityskull vasculaturefemur bone marrowpregnancy-induced bone marrow changesstrokechronic myeloid leukaemiaageing-resistant haematopoiesisbone marrow expansionanatomical compartmentalizationfunctional resilience
Badge
#12 of 6,270
5318m citations

Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML

Jad Othman et al.Blood202410.1182/blood.2024024310

Richard DillonKing's College London, United Kingdom

NPM1-mutated AMLFLT3-internal tandem duplicationMeasurable residual disease (MRD)DNMT3AWT1 mutationnon-ABD NPM1 mutationAdverse-risk cytogeneticscumulative incidence of relapseOverall survivalAllogeneic hematopoietic stem cell transplantation (allo-HSCT)FLAG-Ida regimenfludarabinecytarabineidarubicinpostinduction MRD statusRisk stratificationIntensive chemotherapymolecular subgroupsFirst complete remission
Badge
#13 of 6,270
5018m citations

A new genomic framework to categorize pediatric acute myeloid leukemia

Masayuki Umeda, Jing Ma et al.Nature Genetics202410.1038/s41588-023-01640-3

Jeffery M. KlcoSt. Jude Children's Research Hospital, United States

Pediatric AMLpAML genomic landscapeMolecular classificationUBTFBCL11BHOXA expression signatureHOXB expression signatureRAS pathway genesFLT3WT1mutational patternsexpression profilesMeasurable residual disease (MRD)prognostic frameworkpediatric-specific driver alterations
Badge
#14 of 6,270
4618m citations

Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission

Jad Othman et al.Blood202410.1182/blood.2023023096

Jad OthmanKing's College London, United Kingdom

NPM1-mutated AMLAllogeneic transplant in first complete remissionMeasurable residual disease (MRD)quantitative reverse transcription polymerase chain reactionFLT3-internal tandem duplicationpostinduction MRD statusperipheral blood NPM1 MRDOverall survivalFLT3 allelic ratioNCRI-AML17 trialUK National Cancer Research Institute AML19molecular MRDInduction chemotherapyMRD-positive patientsMRD-negative patientstransplant selection criteria
Badge
#15 of 6,270
4018m citations

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

Min Chul Kwon et al.Blood202410.1182/blood.2023022480

Min Chul KwonJanssen R&D, Belgium

JNJ-75276617bleximenibMenin inhibitorKMT2A-rearranged leukemiaNPM1-mutated AMLprotein-protein interaction inhibitorMEIS1FLT3Acute myeloid leukemia (AML)acute lymphoblastic leukemiagilteritinibVenetoclaxAzacitidineMEN1M327I mutationMEN1T349M mutationrevumenib resistancePatient-derived xenograft modelschromatin binding inhibitioncocrystal structuredrug synergy
Badge
#16 of 6,270
4018m citations

Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones

Aleksandr Ianevski, Kristen Nader et al.Nature Communications202410.1038/s41467-024-52980-5

Tero AittokallioUniversity of Helsinki, Finland

scTherapySingle-cell RNA sequencingintratumoral heterogeneitymulti-targeting therapiesPersonalized treatment regimensAcute myeloid leukemia (AML)high-grade serous ovarian carcinomacancer clonesdrug synergyDrug resistance mechanismsselective co-inhibitionmachine learning predictionprimary patient cellsnormal cell toxicityHematologic malignanciessolid tumorscombinatorial drug screeningpan-cancer analysispathway co-inhibitors
Badge
#17 of 6,270
3718m citations

Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Bofei Wang, Patrick K Reville et al.Nature Communications202410.1038/s41467-024-45916-6

Hussein A. AbbasThe University of Texas MD Anderson Cancer Center, United States

IFNγ signalingAcute myeloid leukemia (AML)monocytic AMLT cellsNK cellsvenetoclax resistancebone marrow microenvironmentsingle-cell analysisImmunosuppressionIFNγ signaling scoreprimary AML patient cellsimmune evasionIFNγ inhibitionprognostic biomarkerBulk RNA sequencingtumor surveillance
Badge
#18 of 6,270
3718m citations

Measurable Residual <i>FLT3</i> Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Laura W Dillon et al.JAMA Oncology202410.1001/jamaoncol.2024.0985

Christopher S. HouriganNational Institutes of Health, United States

FLT3 internal tandem duplication (FLT3-ITD)Acute myeloid leukemia (AML)AMLMeasurable residual disease (MRD)Allogeneic hematopoietic stem cell transplantation (allo-HSCT)First complete remissionVariant allele fractionVAFDNA sequencingRelapseOverall survivalreduced-intensity conditioningmyeloablative conditioningnonmyeloablative conditioningmelphalantransplant conditioning intensificationPre-MEASURE study
Badge
#19 of 6,270
3618m citations

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Jan-Niklas Eckardt et al.npj Digital Medicine202410.1038/s41746-024-01076-x

Jan‐Niklas EckardtTechnical University Dresden, Germany

synthetic data generationAcute myeloid leukemia (AML)generative artificial intelligenceCTAB-GAN+normalizing flowssynthetic control cohortsmultimodal clinical datasurvival analysispatient re-identificationHamming distancesmolecular variablescytogenetic variablesMulticenter clinical trialrare diseasesdata privacyData fidelityusability metricsunivariable outcome analysisinter-variable relationships
Badge
#20 of 6,270
3618m citations

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Matthias Stelljes et al.The Lancet Haematology202410.1016/s2352-3026(24)00065-6

Johannes Schetelig, Johannes ScheteligUniversity Hospital Münster, Germany

Acute myeloid leukemia (AML)allogeneic haematopoietic stem cell transplantationhigh-dose cytarabinesalvage chemotherapymitoxantroneInduction chemotherapywatchful waitingdisease controlnon-inferiority trialComplete remission (CR)Relapsed AMLpoor responsive acute myeloid leukaemiaintensive conditioningTreatment responsenon-favourable-risk acute myeloid leukaemiatreatment-related complicationsprogressive acute myeloid leukaemiaintention-to-transplant
Badge

Dominant research themes and year-over-year shifts in Acute Myeloid Leukemia Research

What Topics Define the Class of 2026?

The 2026 cohort of high-impact acute myeloid leukemia (AML) research is anchored by minimal residual disease (MRD) tracking and combination targeted therapy regimens. Measurable residual disease (MRD) monitoring stands out as the single most prevalent informative focus (24% paper frequency, 12 mentions), underscoring a field-wide transition toward precise molecular response criteria and ultra-sensitive relapse risk stratification post-remission. In parallel, BCL-2 inhibitor venetoclax remains a therapeutic centerpiece (24% paper frequency), frequently investigated alongside hypomethylating agents like azacitidine (12% frequency) to optimize low-intensity frontline protocols and overcome clonal resistance. Genomic driver research continues to emphasize FLT3 internal tandem duplication (FLT3-ITD, 12% frequency) and NPM1 mutations, alongside rising interest in KMT2A rearrangements (10% frequency) and novel Menin inhibitors (8% frequency). Therapeutic evaluation heavily relies on leukemia stem cell (LSC) targeting and patient-derived xenograft (PDX) models (8% frequency each) to decipher chemoresistance mechanisms. Collectively, these focal points reflect a paradigm shift in AML oncology away from uniform intensive chemotherapy toward biomarker-driven, low-toxicity regimens that combine epigenetic priming, targeted apoptotic activation, and rigorous longitudinal MRD surveillance.

Leading research themes
Leading research themes

How Did Topics Shift from the Class of 2025 to the Class of 2026?

Comparing top-ranked publications across consecutive cohorts reveals a decisive pivot toward targeted epigenetic reader inhibition and refined molecular subclassifications. The most pronounced expansion occurred in KMT2A rearrangement studies, which surged 5.0-fold from 2% in the Class of 2025 to 10% in the Class of 2026 (5 mentions). This surge closely mirrors the rise of Menin inhibitors (doubling to 8% frequency) and Menin-KMT2A interaction mechanisms, signaling rapid clinical translation of novel targeted therapeutics for genetically defined AML subsets. Secondary FLT3-targeted investigations also gained momentum, with FLT3-internal tandem duplication studies expanding 3.0-fold (to 6% frequency) and gilteritinib evaluation rising 50%. Conversely, exploratory broad-profiling methodologies experienced a relative decline; single-cell RNA sequencing fell from 10% to 6% frequency (-40%), and foundational mutation studies focusing solely on DNMT3A and ASXL1 both decreased by 50% (from 8% to 4%). Similarly, traditional static risk models like the European LeukemiaNet (ELN) classification saw reduced relative prominence (-33%). Overall, topic evolution highlights an accelerating transition from generalized genomics toward mechanism-driven, target-specific interventions tailored to high-risk leukemic drivers.

How topics shifted year over year
How topics shifted year over year
Methodology

PRI identifies high-impact research using a transparent, topic-agnostic framework applied consistently across scientific domains. Bibliographic records are drawn from OpenAlex, including publication dates, citation relationships, and document types.

This ranking covers the Class of 2026 cohort: journal articles published in 2024. Reviews and other non-article document types are excluded to ensure comparability.

Research impact is quantified with an 18-month post-publication citation window—the number of citing works published within 18 months of each paper's publication date. This metric captures early impact while controlling for publication age.

An LLM-based relevance classifier then reviews each candidate's title and abstract to confirm substantive alignment with the target domain. Only papers classified as relevant appear in the final ranking.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459

Full methodologyGitHubbioRxiv preprint

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31.

Methodology
Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459